Treatment-Dose LMWH versus Prophylactic/Intermediate Dose Heparins in High-Risk COVID-19 Inpatients: Rationale and Design of the HEP-COVID Trial.
Goldin M, Giannis D, Diab W, Wang J, Khanijo S, Sharifova G, Cohen M, Lund JM, Mignatti A, Gianos E, Tafur A, Lewis PA, Cohoon K, Kittelson JM, Lesser ML, Sison CP, Rahman H, Ochani K, Hiatt WR, Dale RA, Anderson VE, Bonaca M, Halperin JL, Weitz JI, Spyropoulos AC.
Goldin M, et al. Among authors: mignatti a.
Thromb Haemost. 2021 Dec;121(12):1684-1695. doi: 10.1055/a-1475-2351. Epub 2021 May 28.
Thromb Haemost. 2021.
PMID: 33823560